Crescent Capital BDC, Inc. (CCAP) is a business development company that provides debt financing to U.S. middle-market companies, with a portfolio concentrated in senior secured and unitranche loans, the large majority of which carry floating rates. On Tuesday, shares of the specialty lender surged approximately 6.28%, trading near $9.82 after closing the prior session at $9.24. The rally was driven by third-quarter results reported after Monday's close, which showed net investment income ahead of analyst expectations, alongside new shareholder-friendly capital-return initiatives.
The clearest catalyst behind the price rally was an earnings-driven move. Crescent Capital BDC reported net investment income of $0.37 per share for the quarter ended September 30, 2026, exceeding the consensus estimate of $0.35 by roughly $0.02. Total investment income came in at approximately $36.9 million, also modestly above analyst projections. While net income of $0.27 per share reflected realized and unrealized losses on portfolio holdings, the headline NII beat reassured investors about the company's ability to cover its distribution.
Management reinforced that message by declaring a fourth-quarter 2026 base dividend of $0.34 per share, payable in January 2027, and confirming a final $0.03 special dividend. For income-focused BDC investors, the confirmation of a substantial dividend yield — even after a period of distribution resets — was a meaningful positive signal that helped fuel the day's advance.
A second driver of the share-price move was the announcement of new capital-return commitments. The board authorized a $50 million share repurchase program to be executed through an independent third-party broker under a Rule 10b5-1 trading plan. Separately, Sun Life intends to purchase up to an additional $25 million of common stock in the open market.
This matters because CCAP trades at a substantial discount to its net asset value of $17.72 per share at quarter-end — the stock was priced near $9.82, well below that book value. Buyback authorizations at such depressed levels are often read by the market as a sign that insiders view the shares as undervalued, which supported investor sentiment during the session.
The move marked a sharp reversal from the stock's recent weakness. Over the prior three months, CCAP had declined roughly 18%, and it was down about 35% over the trailing 12 months amid broader pressure on business development companies tied to credit concerns and rising funding costs. Against that backdrop, Tuesday's gain represented a relief rally rather than a move to new highs.
Trading activity picked up noticeably as investors reacted to the earnings release and buyback news, extending the after-hours advance seen Monday evening. The stock's advance was company-specific in nature — driven by the earnings beat and capital-return announcements — rather than a reflection of a broad sector catalyst, though the BDC group has at times moved in sympathy with shifting expectations around benchmark interest rates given the prevalence of floating-rate loans in these portfolios.
Looking ahead, attention will turn to management's commentary on the earnings conference call, particularly around portfolio credit quality, non-accruals, and the trajectory of net asset value, which declined to $17.72 from $19.10 at the end of 2025. Leverage remains a point of focus, with a net debt-to-equity ratio of 1.36x at quarter-end, and investors will watch whether the buyback is executed aggressively enough to narrow the persistent discount to NAV.
Risks remain. The portfolio has seen markdowns and realized losses in recent quarters, and net income per share has at times lagged the regular dividend. Consensus analyst ratings on the stock are predominantly neutral to positive, but several firms have trimmed price targets over the past two months amid lingering credit stress concerns. The direction of interest rates will also remain a key variable given the floating-rate composition of the loan book. As always, future earnings reports and dividend declarations will be central to sustaining or reversing the current momentum.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently performing strongly under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols traded. Only the strongest performers are featured in this section, giving traders a focused view of strategies that are working right now. Explore the page to see which AI robots are leading today's market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CCAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 22 of 33 cases where CCAP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CCAP as a result. In 45 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for CCAP just turned positive on October 27, 2026. Looking at past instances where CCAP's MACD turned positive, the stock continued to rise in 19 of 43 cases over the following month. The odds of a continued upward trend are 44%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCAP advanced for three days, in 174 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The 10-day RSI Indicator for CCAP moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 16 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 58 cases where CCAP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
CCAP moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCAP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for CCAP entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. CCAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.526) is normal, around the industry mean (2.412). P/E Ratio (-104.222) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.892) is also within normal values, averaging (1.319). Dividend Yield (0.145) settles around the average of (0.270) among similar stocks. P/S Ratio (51.282) is also within normal values, averaging (15.694).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which invests in secured and unsecured debt and related equity securities.
Industry InvestmentManagers